Donanemab therapy lowered brain amyloid levels and slowed cognitive decline in patients with early symptomatic Alzheimer disease over 76 weeks. Lower posttreatment amyloid levels were linked to greater reductions in plasma p-tau217, p-tau181, and GFAP. The post hoc analysis suggested that posttreatment amyloid burden may serve as a surrogate biomarker for treatment efficacy in amyloid-targeting therapies.

Source: JAMA Neurology